Skip to main content

Advertisement

Log in

Activation of Nicotinic Receptors Inhibits TNF-α-Induced Production of Pro-inflammatory Mediators Through the JAK2/STAT3 Signaling Pathway in Fibroblast-Like Synoviocytes

  • Published:
Inflammation Aims and scope Submit manuscript

Abstract

It was recently demonstrated that stimulation of the nicotine receptor attenuates collagen-induced arthritis and inhibits cytokine release in mice. We elucidated the possible intracellular signaling mechanism of the cholinergic anti-inflammatory pathway in fibroblast-like synoviocytes (FLSs). Levels of interleukin (IL)-6, IL-10, and monocyte chemoattractant protein (MCP)-1 in culture supernatants of tumor necrosis factor (TNF)-α-stimulated FLSs were measured using an enzyme-linked immunosorbent assay (ELISA). FLSs were transfected with a small interfering RNA oligonucleotide (STAT3 siRNA or control siRNA). AG490, a specific inhibitor of JAK2, was added 16 h before nicotine, and blocker of nAChR was added 30 min before nicotine. Activation of signal transducers and activators of transcription (STAT) such as STAT1 and STAT3 were detected using Western blotting. Nicotine downregulated production of IL-6 and MCP-1 in RA-FLSs induced by TNFα in a concentration-dependent manner, and IL-10 levels were not significantly different after nicotine pretreatment. Nicotine-induced activation of STAT3 (but not STAT1) and deactivation of STAT3 decreased the anti-inflammatory effect of nicotine. AG490 inhibited the phosphorylation of STAT1 and STAT3 and decreased the TNF-α-induced production of pro-inflammatory mediators in RA-FLSs. A α7nAChR antagonist abrogated the anti-inflammatory effects of nicotine and suppressed STAT3 activity. In conclusion, nicotine has an anti-inflammatory effect on RA by downregulating production of IL-6 and MCP-1 in FLSs, and this is mediated through activation of the JAK2–STAT3 signal pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Choy, E.H., and G.S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine 344(12): 907–916.

    Article  CAS  PubMed  Google Scholar 

  2. Zwerina, J., K. Redlich, G. Schett, et al. 2005. Pathogenesis of rheumatoid arthritis: targeting cytokines. Annals of the New York Academy of Sciences 1051: 716–729.

    Article  CAS  PubMed  Google Scholar 

  3. Feldmann, M., F.M. Brennan, and R.N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annual Review of Immunology 14: 397–440.

    Article  CAS  PubMed  Google Scholar 

  4. Volin, M.V., N. Huynh, K. Klosowska, et al. 2007. Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis and Rheumatism 56(8): 2512–2522.

    Article  CAS  PubMed  Google Scholar 

  5. Mor, A., S.B. Abramson, and M.H. Pillinger. 2005. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clinical Immunology 115(2): 118–128.

    Article  CAS  PubMed  Google Scholar 

  6. Miyazawa, K., A. Mori, H. Miyata, et al. 1998. Regulation of interleukin-1beta-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase. Journal of Biological Chemistry 273(38): 24832–24838.

    Article  CAS  PubMed  Google Scholar 

  7. Miyazawa, K., A. Mori, K. Yamamoto, et al. 1998. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-kappaB and CBF1. American Journal of Pathology 152(3): 793–803.

    CAS  PubMed Central  PubMed  Google Scholar 

  8. Berckmans, R.J., R. Nieuwland, M.C. Kraan, et al. 2005. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Research and Therapy 7(3): R536–R544.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Pavlov, V.A., H. Wang, C.J. Czura, et al. 2003. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Molecular Medicine 9(5–8): 125–134.

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Tracey, K.J. 2002. The inflammatory reflex. Nature 420(6917): 853–859.

    Article  CAS  PubMed  Google Scholar 

  11. Ulloa, L. 2005. The vagus nerve and the nicotinic anti-inflammatory pathway. Nature Reviews Drug Discovery 4(8): 673–684.

    Article  CAS  PubMed  Google Scholar 

  12. van Westerloo, D.J., I.A. Giebelen, S. Florquin, et al. 2005. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. Journal of Infectious Diseases 191(12): 2138–2148.

    Article  PubMed  Google Scholar 

  13. Borovikova, L.V., S. Ivanova, M. Zhang, et al. 2000. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405(6785): 458–462.

    Article  CAS  PubMed  Google Scholar 

  14. de Jonge, W.J., E.P. van der Zanden, F.O. The, et al. 2005. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nature Immunology 6(8): 844–851.

    Article  PubMed  Google Scholar 

  15. Wang, H., M. Yu, M. Ochani, et al. 2003. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421(6921): 384–388.

    Article  CAS  PubMed  Google Scholar 

  16. van Maanen, M.A., M.C. Lebre, T. van der Poll, et al. 2009. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis and Rheumatism 60(1): 114–122.

    Article  PubMed  Google Scholar 

  17. Li, T., X. Zuo, Y. Zhou, et al. 2010. The vagus nerve and nicotinic receptors involve inhibition of HMGB1 release and early pro-inflammatory cytokines function in collagen-induced arthritis. Journal of Clinical Immunology 30(2): 213–220.

    Article  PubMed  Google Scholar 

  18. Waldburger, J.M., D.L. Boyle, V.A. Pavlov, et al. 2008. Acetylcholine regulation of synoviocyte cytokine expression by the alpha7 nicotinic receptor. Arthritis and Rheumatism 58(11): 3439–3449.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Lindblad, S.S., P. Mydel, I.M. Jonsson, et al. 2009. Smoking and nicotine exposure delay development of collagen-induced arthritis in mice. Arthritis Research and Therapy 11(3): R88.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Wang, H., H. Liao, M. Ochani, et al. 2004. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nature Medicine 10(11): 1216–1221.

    Article  CAS  PubMed  Google Scholar 

  21. Darnell, J.J. 1997. STATs and gene regulation. Science 277(5332): 1630–1635.

    Article  CAS  PubMed  Google Scholar 

  22. Levy, D.E., and J.J. Darnell. 2002. Stats: transcriptional control and biological impact. Nature Reviews Molecular Cell Biology 3(9): 651–662.

    Article  CAS  PubMed  Google Scholar 

  23. Katze, M.G., Y. He, and M.J. Gale. 2002. Viruses and interferon: a fight for supremacy. Nature Reviews Immunology 2(9): 675–687.

    Article  CAS  PubMed  Google Scholar 

  24. Decker, T., S. Stockinger, M. Karaghiosoff, et al. 2002. IFNs and STATs in innate immunity to microorganisms. Journal of Clinical Investigation 109(10): 1271–1277.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Kasperkovitz, P.V., N.L. Verbeet, T.J. Smeets, et al. 2004. Activation of the STAT1 pathway in rheumatoid arthritis. Annals of the Rheumatic Diseases 63(3): 233–239.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. van der Pouw, K.T., F.A. van Gaalen, P.V. Kasperkovitz, et al. 2003. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis and Rheumatism 48(8): 2132–2145.

    Article  Google Scholar 

  27. Fahmy, R.G., A. Waldman, G. Zhang, et al. 2006. Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. Nature Biotechnology 24(7): 856–863.

    Article  CAS  PubMed  Google Scholar 

  28. Kano, A., M.J. Wolfgang, Q. Gao, et al. 2003. Endothelial cells require STAT3 for protection against endotoxin-induced inflammation. Journal of Experimental Medicine 198(10): 1517–1525.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Macha, M.A., A. Matta, J. Kaur, et al. 2011. Prognostic significance of nuclear pSTAT3 in oral cancer. Head and Neck 33(4): 482–489.

    Article  PubMed  Google Scholar 

  30. Arredondo, M., G.M. LaPorte, J.D. Wilson, et al. 2006. Analytical methods used for the discrimination of substances suspected to be bar soap: a preliminary study. Journal of Forensic Science 51(6): 1334–1343.

    Article  CAS  Google Scholar 

  31. Chen, G. 2008. Cryopreservation of human pluripotent stem cells in defined conditions.:

  32. Luo, X., X. Zuo, Y. Zhou, et al. 2008. Extracellular heat shock protein 70 inhibits tumour necrosis factor-alpha induced proinflammatory mediator production in fibroblast-like synoviocytes. Arthritis Research and Therapy 10(2): R41.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Koch, A.E., S.L. Kunkel, L.A. Harlow, et al. 1992. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. Journal of Clinical Investigation 90(3): 772–779.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Matsuno, H., K. Yudoh, R. Katayama, et al. 2002. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) 41(3): 329–337.

    Article  CAS  Google Scholar 

  35. Kobelt, G., K. Eberhardt, and P. Geborek. 2004. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Annals of the Rheumatic Diseases 63(1): 4–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Emery, P., E. Keystone, H.P. Tony, et al. 2008. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Annals of the Rheumatic Diseases 67(11): 1516–1523.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Distler, J.H., A. Jungel, L.C. Huber, et al. 2005. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proceedings of the National Academy of Sciences of the United States of America 102(8): 2892–2897.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. van Maanen, M.A., M.J. Vervoordeldonk, and P.P. Tak. 2009. The cholinergic anti-inflammatory pathway: towards innovative treatment of rheumatoid arthritis. Nature Reviews. Rheumatology 5(4): 229–232.

    Article  PubMed  Google Scholar 

  39. Scheid, C., R. Young, R. McDermott, et al. 1994. Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunology, Immunotherapy 38(2): 119–126.

    CAS  PubMed  Google Scholar 

  40. Takeda, K., T. Kaisho, N. Yoshida, et al. 1998. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. Journal of Immunology 161(9): 4652–4660.

    CAS  Google Scholar 

  41. Wong, P.K., J.M. Quinn, N.A. Sims, et al. 2006. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis and Rheumatism 54(1): 158–168.

    Article  CAS  PubMed  Google Scholar 

  42. Cai, J.P., S. Hudson, M.W. Ye, et al. 1996. The intracellular signaling pathways involved in MCP-1-stimulated T cell migration across microvascular endothelium. Cellular Immunology 167(2): 269–275.

    Article  CAS  PubMed  Google Scholar 

  43. Kunkel, S.L., N. Lukacs, T. Kasama, et al. 1996. The role of chemokines in inflammatory joint disease. Journal of Leukocyte Biology 59(1): 6–12.

    CAS  PubMed  Google Scholar 

  44. Ogata, H., M. Takeya, T. Yoshimura, et al. 1997. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. Journal of Pathology 182(1): 106–114.

    Article  CAS  PubMed  Google Scholar 

  45. Lubberts, E., L.A. Joosten, L. Van Den Bersselaar, et al. 2000. Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw. Clinical and Experimental Immunology 120(2): 375–383.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Takeda, K., B.E. Clausen, T. Kaisho, et al. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10(1): 39–49.

    Article  CAS  PubMed  Google Scholar 

  47. Wong, W.S., and K.P. Leong. 2004. Tyrosine kinase inhibitors: a new approach for asthma. Biochimica et Biophysica Acta 1697(1–2): 53–69.

    Article  CAS  PubMed  Google Scholar 

  48. Parganas, E., D. Wang, D. Stravopodis, et al. 1998. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93(3): 385–395.

    Article  CAS  PubMed  Google Scholar 

  49. Simon, A.R., U. Rai, B.L. Fanburg, et al. 1998. Activation of the JAK-STAT pathway by reactive oxygen species. American Journal of Physiology 275(6 Pt 1): C1640–C1652.

    CAS  PubMed  Google Scholar 

  50. Shaw, S., M. Bencherif, and M.B. Marrero. 2002. Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid. Journal of Biological Chemistry 277(47): 44920–44924.

    Article  CAS  PubMed  Google Scholar 

  51. Pesu, M., A. Laurence, N. Kishore, et al. 2008. Therapeutic targeting of Janus kinases. Immunology Reviews 223: 132–142.

    Article  CAS  Google Scholar 

  52. Yamaoka, K., and Y. Tanaka. 2009. Jak inhibitor; possibility and mechanism as a new disease modifying anti-rheumatic drug. Nihon Rinshō Men’eki Gakkai Kaishi 32(2): 85–91.

    Article  CAS  PubMed  Google Scholar 

  53. Garber, K. 2011. Pfizer’s JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nature Biotechnology 29(6): 467–468.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to the patients for their co-operation in this study. This work was supported by grant from the National Natural Science Foundation of China (30671947,81102261).

Competing Interests

The authors declare that they have no conflict of interests regarding the publications of this paper.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Xiaoxia Zuo or Xianzhong Xiao.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, T., Wu, S., Zhang, H. et al. Activation of Nicotinic Receptors Inhibits TNF-α-Induced Production of Pro-inflammatory Mediators Through the JAK2/STAT3 Signaling Pathway in Fibroblast-Like Synoviocytes. Inflammation 38, 1424–1433 (2015). https://doi.org/10.1007/s10753-015-0117-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10753-015-0117-1

KEY WORDS

Navigation